Smoking Among UK Students at Historic Low: NHS Digital

Sep.07.2022
Smoking Among UK Students at Historic Low: NHS Digital
Smoking among school students in England has hit a record low at 3%, according to NHS Digital. However, over 20% of 15-year-old girls now use e-cigarettes, which is reminiscent of smoking levels over a decade ago. The statistics also show progress in reducing underage drinking and drug use.

Newly released statistics from NHS Digital have revealed that the proportion of smoking students has hit a record low of 3%. However, alarmingly, over 20% of 15-year-old girls are now using e-cigarettes, bringing to mind the smoking levels seen over a decade ago. This data suggests a worrying trend towards a new form of nicotine addiction among young people. Photo credit: David Jones/PA.


A study has revealed that in 2021, 21% of 15-year-old girls admit to currently using electronic cigarettes, more than twice the amount recorded by NHS Digital in 2018 (10%). The percentage of girls using e-cigarettes is 7 percentage points higher than their male peers of the same age.


The 2021 report on smoking, drinking, and drug use among young people in England shows a decrease in the percentage of students who self-report as smokers from 5% in 2018 to 3% in 2021, reaching an all-time low. As of 2021, less than one-eighth of secondary school students (12%) have ever smoked, which is the lowest number since comparable records began in 1982.


The number of people using electronic cigarettes has reached a historical high. In 2021, 9% of students have tried e-cigarettes, which is the highest number on record, compared to 6% in 2018. Girls aged 15 are most likely to do so, with over one-fifth of people reporting current use and 12% saying they use e-cigarettes frequently. The last time regular smoking rates were this high among 15-year-old girls was in 2010, when 14% reported being regular smokers.


However, the study also revealed progress in reducing alcohol and drug use. According to new data released by NHS Digital, only 18% of 11 to 15-year-old teenagers in England reported having used drugs by 2021, down from 24% in 2018. Last year, only 40% of students reported having drunk alcohol, down from 44% in both 2018 and 2016.


According to data, high school students with stronger social skills- those who frequently interact with people outside of their family or school- are more likely to have tried illegal drugs, alcohol, or smoking compared to those who rarely meet others. Among those who interact with people outside of their family or school on a daily basis, nearly one-fifth (19%) have used drugs in the past month. In contrast, 8% of those who socialize outside of their home or school a few times a week and 5% of those who only meet with people outside of their home or school once a week have used drugs in the past month. Among those who have not met anyone in the past month, only 2% have used drugs.


According to statistical data, Covid-19 may have played a role in the decrease in drug usage, as the early 2021 restrictions may have limited young people's opportunities to socialize outside of school. The proportion of students who have tried nitrous oxide (known as laughing gas) has decreased significantly. In 2021, only 3% of students had tried it, a decrease of 2.8 percentage points since 2018. The proportion of high school students who have tried glue and solvents has decreased by 2.2 percentage points to 6.8%, while cocaine usage has decreased from 1.8% to 1.4%.


Reducing drug use, alcohol consumption and smoking may have a positive impact on the mental health and well-being of young people. Last month, more than half of children who used drugs reported low levels of happiness during that time, while only 26% of children who did not smoke, drink or use drugs reported feeling happy.


Statement


This article is compiled from third-party information and is intended for industry discussion and learning purposes.


This article does not necessarily reflect the viewpoint of 2FIRSTS and we cannot confirm the authenticity and accuracy of its content. The translation of this article is solely for the purpose of industry exchange and research.


Due to limitations in our translation abilities, the translated version of this article may not accurately reflect the original text. Please refer to the original article for accuracy.


2FIRSTS aligns completely with the Chinese government on any domestic, Hong Kong, Macao, Taiwan, and foreign issues and positions.


The copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Technology reported FY2026 revenue of about $96 million, down 24.7% year over year, as U.S. cannabis-vapor hardware and European e-cigarette sales declined by $17.4 million and $12.7 million, respectively. Fourth-quarter revenue rose 32.5% to $26.7 million, while quarterly gross margin fell to 6.3%. For FY2027, the company is prioritizing Malaysia manufacturing and vapor ODM while continuing to develop nicotine pouches, IKE Tech age-verification technology and G-Mesh licensing. Ispire has not separately disclosed the revenue or profit contribution of those newer businesses.
Regulations
Sep.17 by 2Firsts Perspectives
F1 Faces Renewed Pressure Over Tobacco and Nicotine Sponsorships as 67 Groups Target ZYN and VELO Ahead of Madrid Race
F1 Faces Renewed Pressure Over Tobacco and Nicotine Sponsorships as 67 Groups Target ZYN and VELO Ahead of Madrid Race
Ahead of the Formula 1 race in Madrid, 67 Spanish and international public-health, medical and consumer organizations have sent an open letter to F1 President and CEO Stefano Domenicali calling for an end to sponsorships linked to the tobacco and nicotine industry, including nicotine pouches, vaping products and heated tobacco. The letter focuses on Philip Morris International’s ZYN partnership with Ferrari and British American Tobacco’s long-running partnership with McLaren and exposure for VELO. The campaign follows a March letter in which more than 160 organizations worldwide made a similar request to Formula 1.
Sep.10
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
Cliff Douglas, a veteran U.S. tobacco-control and public health policy figure, told NAS 2026 that the “continuum of risk” should play a central role in tobacco policy. He called for clearer market pathways, stronger risk communication, differentiated regulation and enforcement, and said possible FDA reforms to PMTA reviews could be a “welcome correction” if they create a more efficient, predictable route for scientifically substantiated lower-risk products. Read 2Firsts’ on-site coverage.
Sep.26
Philippines Mandates Safety Certification for Nicotine Pouches, Gives Industry 12 Months to Comply
Philippines Mandates Safety Certification for Nicotine Pouches, Gives Industry 12 Months to Comply
The Philippines Department of Trade and Industry has placed nicotine pouches under mandatory product certification through Department Administrative Order No. 26-07, Series of 2026. Nicotine pouches must obtain a Philippine Standard, or PS, license before they can be manufactured, imported, packed, distributed or sold in the country. The regime requires testing for nicotine content, pH and water activity, while packaging must disclose nicotine strength, ingredients, allergens, batch information, the PS certification mark and prescribed health warnings. Existing market participants have a 12-month transition period to comply.
Regulations
Oct.12
Altria’s USSTC Starts $250 Million Kentucky Expansion, Adding More Than 200 Jobs
Altria’s USSTC Starts $250 Million Kentucky Expansion, Adding More Than 200 Jobs
U.S. Smokeless Tobacco Company, an Altria Group company, has broken ground on an approximately $250 million manufacturing expansion in Hopkinsville, Kentucky. The roughly 270,000-square-foot facility is expected to create more than 200 jobs and absorb processing, manufacturing and packaging operations currently split between Hopkinsville and Nashville, Tennessee. USSTC previously said production at its Nashville facility is expected to wind down by early 2028. The project forms part of Altria’s broader effort to modernize and consolidate its U.S. smokeless tobacco manufacturing network.
Sep.10
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Philip Morris International (PMI) has launched ZYN Melts in the UK, introducing a fully dissolvable oral nicotine tablet format alongside the brand's existing nicotine pouches. The range includes Cool Mint and Peppermint, each offered at 1mg and 2mg of nicotine per tablet, creating four SKUs. Each can contains 20 tablets and is priced at £6.50 in the UK. Unlike ZYN nicotine pouches, Melts are placed between the upper lip and gum and dissolve completely during use.
News
Sep.29 by 2Firsts Perspectives